People in the News
Life sciences investment group Abingworth Management, which holds a stake in Alnylam Pharmaceuticals, said this week that it has appointed Tim Haines as a partner.
Haines will be responsible for identifying and creating new businesses, as well as providing support for existing companies within the Abingworth portfolio, the firm said.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
